11 active not recruiting. 11 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Active not recruiting 11 |
| Phase 1 | 3 | Active not recruiting 3 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Chronic Hepatitis B: new trials by email Literature Review of Chronic Hepatitis B trials Research Report on Chronic Hepatitis B
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection HT-101, HT-102, HT-101 placebo - Chronic Hepatitis B | Phase 2 | Active not recruiting | Suzhou HepaThera Biotech Co., Ltd. | 60 | 2025-11-05 | 2026-10-29 |
| A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B BW-20507 with/without NUC, BW-20507 with/without NUC, Peg-IFNa - Chronic Hepatitis B | Phase 2 | Active not recruiting | Shanghai Argo Biopharmaceutical Co., Ltd. | 209 | 2025-09-02 | 2026-01-15 |
| A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB) AHB-137 - Chronic Hepatitis B | Phase 2 | Active not recruiting | Ausper Biopharma Co., Ltd. | 20 | 2025-07-15 | 2026-08-10 |
| A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B HTS 20mg, HTS 30mg, HTS 40mg - Chronic Hepatitis B | Phase 2 / Phase 3 | Active not recruiting | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | 1444 | 2025-07-01 | 2025-10-02 |
| VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B VIR-2218 and peginterferon alfa-2a - Chronic Hepatitis B | Phase 2 | Active not recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 12 | 2025-01-31 | 2026-10-05 |
| A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus Infection HT-101, HT-102 - Chronic Hepatitis B | Phase 1 / Phase 2 | Active not recruiting | Suzhou HepaThera Biotech Co., Ltd. | 86 | 2024-12-30 | 2026-10-29 |
| Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B (CHB) AHB-137, NAs, Placebo - Chronic Hepatitis B | Phase 2 | Active not recruiting | Ausper Biopharma Co., Ltd. | 105 | 2024-12-13 | 2026-07-29 |
| Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection Placebo, TQA3334 Tablet, Nucleoside (acid) analogs (NAs) - Chronic Hepatitis B | Phase 2 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 116 | 2024-12-04 | 2026-09-11 |
| A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B Placebo, TQA3605 tablets, Entecavir dispersible tablets - Chronic Hepatitis b | Phase 1 / Phase 2 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 88 | 2023-12-07 | 2024-11-14 |
| Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104 ISA104, Placebo - Chronic Hepatitis b | Phase 1 / Phase 2 | Active not recruiting | Erasmus Medical Center | 24 | 2023-08-04 | 2026-09-15 |
| Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection TAF, Placebo - Chronic Hepatitis B | Phase 2 | Active not recruiting | Gilead Sciences | 150 | 2016-11-01 | 2026-06-18 |
Hepatitis B, Chronic (11)
Blood-Borne Infections (11) · Chronic Disease (11) · Communicable Diseases (11) · DNA Virus Infections (11) · Digestive System Diseases (11) · Disease Attributes (11) · Hepadnaviridae Infections (11) · Hepatitis (11) · Hepatitis B (11) · Hepatitis, Chronic (11) · Hepatitis, Viral, Human (11) · Infections (11) · Liver Diseases (11) · Pathologic Processes (11) · Pathological Conditions, Signs and Symptoms (11)
Acids (1) · Nucleosides (1) · Saline Solution, Hypertonic (1) · Tenofovir (1) · entecavir (1) · nas (1) · peginterferon alfa-2a (1)
Ausper Biopharma Co., Ltd. (2) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2) · Suzhou HepaThera Biotech Co., Ltd. (2) · Erasmus Medical Center (1) · Gilead Sciences (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Shanghai Argo Biopharmaceutical Co., Ltd. (1) · Xi'an Xintong Pharmaceutical Research Co.,Ltd. (1)
China (8) · United States (2) · Belgium (1) · Hong Kong (1) · India (1) · Netherlands (1) · Romania (1) · Russia (1) · South Korea (1) · Taiwan (1)
Dave Sprengers, MD, PhD (1) · Dazhi Zhang (1) · Jinlin Hou (1) · Marc G Ghany, M.D. (1)
2016 (1), 2023 (1)